tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NeuPath Health Reports Record Revenue and Growth in Q2 2025

Story Highlights
NeuPath Health Reports Record Revenue and Growth in Q2 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Neupath Health Inc. ( (TSE:NPTH) ) has provided an update.

NeuPath Health Inc. reported record second-quarter revenue of $23.6 million, marking a 25% increase year-over-year, alongside a 69% rise in adjusted EBITDA to $2.2 million. The company’s improved financial performance is attributed to increased capacity utilization and strong demand for Arthrosamid, positioning NeuPath for continued growth and strategic expansion in the latter half of 2025.

The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.

More about Neupath Health Inc.

NeuPath Health Inc. operates a network of clinics specializing in chronic pain treatment. The company focuses on optimizing patient outcomes and enhancing clinic operations, with a market emphasis on innovative procedures such as Arthrosamid.

Average Trading Volume: 84,534

Technical Sentiment Signal: Buy

Current Market Cap: C$13.12M

For detailed information about NPTH stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1